Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Jiangsu Huili Biotechnology

Request full access

A Hong Kong-based next-generation synthetic biology enzyme computational design platform, completed its Series A financing round with hundreds of million RMB

ChinaBiotech & Life Sciences

About Jiangsu Huili Biotechnology

Jiangsu Huili Biotechnology Co., Ltd., also known as Huili Bio, operates as a high-tech enterprise centered on the application of synthetic biology. The company was established in 2018 and is headquartered in Taizhou, China, with a key research and development center located in Tianjin. The legal representative and chairman is Guo Hongming. The company's core team is composed of individuals from domestic universities, the Chinese Academy of Sciences, and other research institutions.

Huili Bio specializes in the research, development, and industrial application of biotechnology, focusing on the creation of industrial enzyme preparations. Its business model revolves around providing sustainable, bio-manufacturing solutions for various sectors, including pharmaceutical intermediates, animal health, functional foods, new materials, and environmental preservation. A significant milestone was achieved in July 2022, when the company secured hundreds of millions of RMB in a Series A financing round. This funding was co-led by Legend Capital and BioTrack Capital, with participation from others, and was earmarked for expanding large-scale production facilities, advancing the R&D of new product pipelines, and growing the team.

The company's principal offering is its proprietary artificial intelligence industrial enzyme computing design platform. This platform facilitates the computational design of enzyme components, which are crucial for synthetic biological reactions. It enables the company to develop and commercialize products with higher efficiency and lower costs compared to traditional chemical synthesis—reportedly reducing costs by nearly 30% and increasing yields by almost 70%. Through this technology, Huili Bio has developed over 10 products with independent intellectual property rights. Their product portfolio includes pharmaceutical intermediates such as Acamprosate and Oritavancin, as well as functional food ingredients and animal health products.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
25.4/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jul 2022 $41M $165M ZWC Partners · Yunqi Partners · Cenova Capital · BioTrack Capital ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Jiangsu Huili Biotechnology website traffic

Latest recorded traffic for Jiangsu Huili Biotechnology is 910 monthly website visits, up 506.7% over the last three months.

Latest monthly visits910 3-month web change+506.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Jiangsu Huili Biotechnology in its local ecosystem

Live from Dealroom

The Jiangsu Huili Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Legend Capital
  • ZWC Partners
  • Yunqi Partners
  • Cenova Capital
  • BioTrack Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Jiangsu Huili Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Jiangsu Huili Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.